Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation.

Using the European Group for Blood and Marrow Transplantation (EBMT) registry, we retrospectively studied 19 patients with AL (amyloid light-chain) amyloidosis who underwent allogeneic (allo; n = 15) or syngeneic (syn; n = 4) hematopoietic stem cell transplantation (SCT) between 1991 and 2003. For allo-SCT, full-intensity conditioning was used in 7 patients and reduced-intensity conditioning (RIC) in 8 patients. Engraftment was durable in 12 of those 15 patients. The median follow-up time is 19 months. Kaplan-Meier probabilities of overall and progression-free survival were 60% and 53% at 1 year, respectively. Overall, 40% of patients died of transplant-related mortality (TRM). Best hematologic response after SCT was complete remission (CR) and partial remission (PR) in 8 and 2 patients, respectively, leading to an organ response in 8 of these patients. Seven of the 10 patients in remission are long-term survivors. In 5 of 7 evaluable patients in CR, chronic graft-versus-host disease (GvHD) was observed, indicating the contribution of immune effects to disease control. The main clinical problem was cardiac failure in patients with poor performance status due to amyloidosis or in combination with severe infections. These data suggest that allo-SCT might be a promising and potentially curative treatment modality for selected patients with AL amyloidosis.

[1]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[2]  R. Falk,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.

[3]  H. Einsele,et al.  Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. , 2005, Blood.

[4]  G. Merlini,et al.  The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). , 2005, Blood.

[5]  G. Damaj,et al.  Long-term successful outcome of sequential cardiac and allogeneic bone marrow transplantations in severe AL amyloidosis , 2005, Bone Marrow Transplantation.

[6]  H. Goldschmidt,et al.  High‐dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study , 2004, British journal of haematology.

[7]  J. Crowley,et al.  Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. , 2004, Blood.

[8]  R. Falk,et al.  Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation , 2004 .

[9]  M. Skinner,et al.  Feasibility of Second Autologous Peripheral Blood Stem Cell (PBSC) Collection Followed by a Second Cycle of High Dose Melphalan (HDM) in Patients Relapsing after an Initial Course of HDM for the Treatment of AL Amyloidosis. , 2004 .

[10]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[11]  C. Flowers,et al.  Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. , 2004, Blood.

[12]  C. Flowers,et al.  Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. , 2004, Blood.

[13]  M. Gertz,et al.  A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study , 2004, Bone Marrow Transplantation.

[14]  H. Arai,et al.  Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high‐dose melphalan , 2004, European journal of haematology.

[15]  T. Therneau,et al.  Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. , 2004, Blood.

[16]  R. Falk,et al.  High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial , 2004, Bone Marrow Transplantation.

[17]  R. Falk,et al.  High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study , 2004, Annals of Internal Medicine.

[18]  R. Fonseca,et al.  Superior Survival in Primary Systemic Amyloidosis Patients Undergoing Peripheral Blood Stem Cell Transplant : A Case Control Study Running Head: Survival in AL, Case Control Study , 2004 .

[19]  R. Storb,et al.  Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  W. Siegert,et al.  Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[22]  M. Pepys,et al.  Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy , 2003, British journal of haematology.

[23]  S. E. Jacobsen,et al.  Human reconstituting hematopoietic stem cells up-regulate Fas expression upon active cell cycling but remain resistant to Fas-induced suppression. , 2003, Blood.

[24]  P. Sonneveld,et al.  Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Falk,et al.  Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. , 2003, Clinical lymphoma.

[26]  J. Ritz,et al.  Allogeneic stem cell transplantation for multiple myeloma. , 2002, Reviews in clinical and experimental hematology.

[27]  M. Gertz,et al.  Autologous stem cell transplantation for primary systemic amyloidosis. , 2002, Blood.

[28]  D. Booth,et al.  Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. , 2002, The New England journal of medicine.

[29]  B. Björkstrand.  European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. , 2001, Seminars in hematology.

[30]  W. Hiddemann,et al.  Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias , 2001, Annals of Hematology.

[31]  G. Gahrton,et al.  Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres , 2001, British journal of haematology.

[32]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[33]  直子 加藤,et al.  Graft-Versus-host Disease , 1999 .

[34]  T. Therneau,et al.  Long-term survival (10 years or more) in 30 patients with primary amyloidosis. , 1999, Blood.

[35]  C. Craddock,et al.  High-dose melphalan and stem cell rescue for AL amyloidosis , 1999 .

[36]  J Hermans,et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.

[37]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[38]  R. Bataille,et al.  Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients , 1998, British journal of haematology.

[39]  N. Russell,et al.  Allogeneic bone marrow transplantation for systemic AL amyloidosis , 1998, British journal of haematology.

[40]  J. Buxbaum,et al.  The systemic amyloidoses. , 1998, The New England journal of medicine.

[41]  M. Jadoul,et al.  Allogeneic bone marrow transplantation for AL amyloidosis , 1997, Bone Marrow Transplantation.

[42]  T. Therneau,et al.  A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. , 1997, The New England journal of medicine.

[43]  H. Goldschmidt,et al.  High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  F. Verzijlbergen,et al.  Clinical Remission after Syngeneic Bone Marrow Transplantation in a Patient with AL Amyloidosis , 1995, Annals of Internal Medicine.

[45]  S M Breathnach,et al.  Amyloid and amyloidosis. , 1988, Journal of the American Academy of Dermatology.

[46]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.